glp 1 and sarcopenia GLP-1-derived therapies sarcopenia: plea for a specific focus on at risk special populations While GLP-1 medications are effective – Muscle Loss with GLP-1 Medications:

Important: Introduce new active skincare ingredients like retinoids or tranexamic acid gradually so you can avoid irritation and monitor any reactions

Its becoming a multi-disease cardiometabolic platform spanning: Cardiovascular disease Obstructive sleep apnoea (OSA) MASH Chronic kidney disease And importantly: Oral obesity therapy is now real not theoretical But the category is already splitting: Peptide oral (with friction) Small-molecule oral (lower friction) That distinction will matter more than pill vs injection Peptide oral (with friction) Small-molecule oral (lower friction) That distinction will matter more than pill vs injection The Most Misunderstood Opportunity: OSA OSA has gone from interesting to commercially meaningful fast Tirzepatide is now the first approved drug for OSA in obesity Phase 3 data showed:~2529 events/hour reduction in AHI Up to ~50% reaching disease-resolution criteria Thats real

In a statement, Ro said, "We are working to ensure patients have access to the most effective medications available and will continue to follow all applicable FDA rules and guidelines." The supply update "starts the clock on having unfettered market access to the patented drug" for companies like Hims & Hers and the broader compounding GLP-1 space, analysts at Leerink Partners wrote in a note to clients Friday morning

Each plan is developed with the individual patient in mind

This is typically the responsibility of the healthcare professional